Track Vor Biopharma Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Vor Biopharma Inc. VOR · Stock Open Vor Biopharma Inc. in new tab

19.42 USD
P/E
0.07
EPS
300.56
P/B
-8.76
ROE
-125.43
Beta
1.83
Target Price
39.00 USD
Loading chart...
Key Metrics
Earnings dateMarch 29, 2027
P/E0.07
EPS300.56
Book Value-2.23
Price to Book-8.76
Debt/Equity46.59
% Insiders8.918%
Estimates
Forward P/E-5.85
Forward EPS-3.34
Target Mean Price39.00

DCF valuation

Model fair value for Vor Biopharma Inc. (VOR)
Result
Sign in to run the valuation for VOR.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
8 analysts · consensus Strong buy · mean target 39.00 USD (low 27.00, high 50.00) · as of 10 Nov 2026
Low 27.00
Mean 39.00
High 50.00
Price 19.42
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Vor Biopharma Inc. Logo Vor Biopharma Inc. Analysis (VOR)

United States Health Care Official Website Stock

Is Vor Biopharma Inc. a good investment? Vor Biopharma Inc. (VOR) is currently trading at 19.42 USD. Market analysts have a consensus price target of 39.00 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 0.07. This relatively low multiple may signal that Vor Biopharma Inc. is undervalued compared to historical market norms.

Earnings Schedule: Vor Biopharma Inc. is expected to release its next earnings report on March 29, 2027. The market consensus estimate for Forward EPS is -3.34.

Investor FAQ

Does Vor Biopharma Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Vor Biopharma Inc.?

Vor Biopharma Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 29, 2027. The company currently has a trailing EPS of 300.56.

Company Profile

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Exchange Ticker
NMS (United States) VOR
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Sept. 19, 2025 1:20
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion